Key Points
- Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies on Feb. 17 at $25.60/share for $384,000, reducing his holdings by 3.8% to 379,786 shares (≈$9.72M); he also sold 15,000 shares on Jan. 15 and Dec. 29, indicating repeated insider sales.
- KMTS recent trading and outlook: the stock was trading at $26.87 (up ~2.1%), has a $1.57B market cap, 52‑week range $13.25–$30.00 and a negative P/E of -8.48; analysts have a "Moderate Buy" consensus with an average target of $29.00.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $25.60, for a total value of $384,000.00. Following the sale, the insider directly owned 379,786 shares in the company, valued at $9,722,521.60. This trade represents a 3.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Brian Daniel Webster also recently made the following trade(s):
- On Thursday, January 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.80, for a total transaction of $342,000.00.
- On Monday, December 29th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $26.59, for a total transaction of $398,850.00.
Kestra Medical Technologies Trading Up 2.1%
NASDAQ KMTS traded up $0.55 during trading hours on Friday, hitting $26.87. 39,303 shares of the company were exchanged, compared to its average volume of 255,815. The stock has a 50-day moving average price of $25.65 and a 200 day moving average price of $23.61. Kestra Medical Technologies, Ltd. has a 52 week low of $13.25 and a 52 week high of $30.00. The stock has a market cap of $1.57 billion and a PE ratio of -8.48. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.26.
Hedge Funds Weigh In On Kestra Medical Technologies
A number of large investors have recently added to or reduced their stakes in KMTS. Farther Finance Advisors LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter worth about $31,000. Russell Investments Group Ltd. boosted its stake in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company's stock worth $41,000 after acquiring an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Kestra Medical Technologies during the third quarter worth approximately $48,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Kestra Medical Technologies in the 2nd quarter valued at $54,000. Finally, BNP Paribas Financial Markets lifted its holdings in Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company's stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter.
Analyst Ratings Changes
A number of analysts have weighed in on KMTS shares. The Goldman Sachs Group set a $24.00 target price on Kestra Medical Technologies in a research note on Friday, January 16th. BTIG Research initiated coverage on Kestra Medical Technologies in a research note on Tuesday, November 18th. They issued a "buy" rating and a $32.00 target price on the stock. Wells Fargo & Company increased their price objective on Kestra Medical Technologies from $27.00 to $28.00 and gave the company an "overweight" rating in a report on Friday, December 12th. Stifel Nicolaus set a $30.00 price target on Kestra Medical Technologies in a report on Friday, December 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Kestra Medical Technologies in a research note on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $29.00.
Read Our Latest Report on KMTS
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
